SLX-0528 / Arrien, Boston Pharma, Xenthera, Biolexis Therap - LARVOL DELTA

Subjects With Advanced or Metastatic Solid Tumor Malignancies (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Xenthera, Inc. | Trial completion date: Jun 2027 ➔ Jun 2028 | Trial primary completion date: Jan 2027 ➔ Jan 2028

Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Subjects With Advanced or Metastatic Solid Tumor Malignancies (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Xenthera, Inc. | Trial completion date: Jun 2026 ➔ Jun 2027 | Trial primary completion date: Jan 2026 ➔ Jan 2027

Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Subjects With Advanced or Metastatic Solid Tumor Malignancies (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Xenthera, Inc. | Initiation date: May 2023 ➔ Nov 2023

Metastases • Trial initiation date • Oncology • Solid Tumor

Pancreatic cancer oral inverse agonist of RORgT receptor targets primary cancer cells and alters inflammatory mediators of the tumor microenvironment (ESMO-GI 2023) - P1 | "The backbone of therapy has been gemcitabine and more recently in combination with Nab-paclitaxel or FOLFIRINOX regimens however the incremental gains in survival range from 2-4.5 months 1,2 with a heavy cost of quality of life due to the side effects... RORgT and the IL-17 pathway is a well-recognized target for inflammatory conditions, and increased expression is associated with a worse prognosis for various cancers. XT-0528 is a high-affinity RORgT inverse agonist with a demonstrated reduction in the key inflammatory cytokine IL-17 and a very good safety profile that is a promising agent for pancreatic cancer. Translational work demonstrates increased RORgT expression in human pancreatic cancer and RORgT inhibition led to tumor regression within a human xenograft tumor model."

Biomarker • IO biomarker • Tumor microenvironment • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • IL17A

Subjects With Advanced or Metastatic Solid Tumor Malignancies (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Xenthera, Inc. | Trial completion date: Oct 2025 ➔ Jun 2026 | Initiation date: Sep 2022 ➔ May 2023 | Trial primary completion date: Aug 2025 ➔ Jan 2026

Metastases • Trial completion date • Trial initiation date • Trial primary completion date • Oncology • Solid Tumor

Subjects With Advanced or Metastatic Solid Tumor Malignancies (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Xenter, Inc.

New P1 trial • Oncology • Solid Tumor

Study to Determine the Relative Bioavailability, Single and Repeat Dose Pharmacokinetics, Safety and Tolerability of BOS172767 Enantiomers in Healthy Subjects (clinicaltrials.gov) - P1; N=12; Completed; Sponsor: Boston Pharmaceuticals

Clinical • New P1 trial